Clinical trials: Recurrent Epithelial Ovarian Cancer
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer.
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Uterine Cancer
- Trial name
- NCT01650376
- Testing
- Olaparib, Carboplatin, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Swedish Medical Center
Ovarian Cancer
Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian…
- Trial name
- NCT00004008
- Testing
- bryostatin 1
- Where
- 4 sites in United Kingdom
- Sponsor
- University of Glasgow
Breast Cancer, Chronic Myeloproliferative Disorders
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: A donor stem cell transplant can lower the body's immune system, making it difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00324324
- Testing
- moxifloxacin hydrochloride
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- OHSU Knight Cancer Institute
Epithelial Ovarian Cancer
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
The purpose of this study is to determine the efficacy and safety of belotecan or topotecan in patients with recurrent or refractory ovarian cancer (AOC).
- Trial name
- NCT01630018
- Testing
- Topotecan, Belotecan
- Where
- South Korea
- Volunteers
- 141 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Adult Solid Neoplasm, Recurrent Ovarian Carcinoma
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
This phase I trial is studying the side effects and best dose of eribulin mesylate and gemcitabine hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Adult Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Ovarian Cancer AJCC v6 and v7
- Trial name
- NCT00410553
- Testing
- Eribulin Mesylate, Gemcitabine Hydrochloride
- Where
- 2 sites in Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Cavity Cancer
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating women who have ovarian epithelial…
- Trial name
- NCT00004081
- Testing
- docetaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Deaconess Medical Center
Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III-IV or recurrent ovarian cancer.
- Conditions
- Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
- Trial name
- NCT01322802
- Testing
- pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Cervical Cancer, Fallopian Tube Cancer
Gefitinib in Treating Patients With Cervical Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of cervical cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00049556
- Testing
- gefitinib, immunohistochemistry staining method, surface-enhanced laser desorption/ionization-time of flight mass spectrometry
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Fatigue
Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer
RATIONALE: Yoga may improve symptoms and quality of life and reduce stress in patients with ovarian cancer or breast cancer and may help them live more comfortably.
- Conditions
- Breast Cancer, Fatigue, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00337233
- Testing
- yoga therapy
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Wake Forest University Health Sciences
Ovarian Cancer, Peritoneal Cavity Cancer
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227721
- Testing
- Docetaxel, Gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Robert Morris
Endometrial Cancer, Ovarian Cancer
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
- Trial name
- NCT07444814
- Testing
- HWK-007
- Where
- 12 sites in United States
- Volunteers
- 226 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Platinum-sensitive Recurrent Ovarian Cancer
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
This is a Phase III study evaluating the efficacy of HS-20089 in combination with bevacizumab versus investigator's choice of platinum-based chemotherapy in combination with bevacizumab in participants with platinum-sensitive…
- Trial name
- HS-20089 PSOC (NCT07821606)
- Testing
- HS-20089+Bevacizumab, Dose 2：arboplatin+Paclitaxel+Bevacizumab, Dose 3：arboplatin+Gemcitabine+Bevacizumab
- Where
- 39 sites in China
- Volunteers
- 460 people
- Sponsor
- Hansoh BioMedical R&D Company
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
This pilot phase I trial studies how well dasatinib works together with paclitaxel and carboplatin in treating patients with stage III, stage IV, or endometrial cancer that has come back after a period of improvement.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01440998
- Testing
- Carboplatin, Dasatinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer.
- Trial name
- TICTOC (NCT05156892)
- Testing
- SUBA-itraconazole, Tamoxifen
- Where
- Australia
- Volunteers
- 44 people
- Sponsor
- Anthony Joshua, FRACP
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Recurrent Gynecologic Cancer, Recurrent Uterine Cancer
Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total…
- Conditions
- Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer
- Trial name
- Regynera-RT (NCT07667192)
- Testing
- Reirradiation, Total Ablative Strategy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic
NR in Chemo-induced Peripheral Neuropathy
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV
- Trial name
- NCT03642990
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Donna Hammond, PhD
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
This is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab/tuvonralimab (QL1706), a bispecific antibody targeting programmed cell death…
- Trial name
- NCT07454018
- Testing
- Iparomlimab/Tuvonralimab
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Fallopian Tube Cancer, Ovarian Cancer
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: AMG 706 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00574951
- Testing
- motesanib diphosphate
- Where
- 19 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.